Gall bladder treatment market information, by disease indications (gallstones, cholecystitis and biliary colic, cholelithiasis and choledocholithiasis, gallbladder polyps, gall bladder cancer), by diagnosis (ultrasound, blood tests, computerized tomography (CT), cholangiography and hepatobiliary scintigraphy), by treatment (surgery, drugs), by end users (hospitals & gynecology clinics, academic & research centers) - Global forecast till 2032

Global Gallbladder Treatment Market Overview

The Gallbladder Treatment Market Size was valued at USD 16.35 Billion in 2023. The Global Gallbladder Treatment industry is projected to grow from USD 17.52 Billion in 2024 to USD 30.32 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.92% during the forecast period (2024 - 2032). The gall bladder is a small pear-shaped located underneath the liver. Its main function is to store the bile produced by liver and pass it along through a duct that empties into the small intestine. Gall bladder diseases affect a large number of people in the world. Gallbladder and biliary related diseases occurred in about 104 million people (1.6%) in 2013 and they resulted in 106,000 deaths.

In April 2024, Madrigal Pharmaceuticals Inc., a biopharmaceutical company focused on providing novel therapies for non-alcoholic steatohepatitis (NASH), announced that resmethrin is now commercially available in the U.S., by brand name Rezdiffra. Rezdiffra is part of an overall treatment plan when combined with a diet and exercise program for adults having non-cirrhotic NASH who have medium-to-severe liver fibrosis consistent with stages F2 through F3 fibrosis. Future authorization depends on confirmation of clinical advantage according to ongoing confirmatory studies.

Eli Lilly and Company’s made Zepbound™ (tripeptide) injection has gotten approval from the U.S. Food and Drug Administration. The first ever anti-obesity drug to target the hormonal GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon like peptide-1). Zepbound may be administered to obese people with a body mass index of 30kg/m2 and above, or overweight individuals with a BMI of 27 kg/m2 and over who also have hypertension, dyslipidemia, type II diabetes mellitus, obstructive sleep apnea or cardiovascular disease. It should be used together with reduced-calorie meals and increased physical exercise. Apart from having no studies conducted on individuals who have previously experienced pancreatitis or severe gastrointestinal diseases such as severe gastroparesis, Zepbound should not coexist with any other tripeptide products or GLP-1 receptor agonists.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the closing of the recently disclosed acquisition of Travere’s bile acid product portfolio by Mirum including their medications Cholbam® (cholic acid) and Chenodal® (chenodiol), that are used for rare diseases in high-need settings. Upon completion of the asset purchase, Mirum paid Travere $210 million upfront, which could result in an additional $235 million in sales-based milestones.

Gallbladder Treatment Market Trends

The major driving factors for the growth of the market are increasing geriatric population, increasing prevalence rate of various gallbladder diseases, and introduction & adoption of advanced diagnostic treatment options. Moreover, increasing awareness of the diseases, rising healthcare expenditure, and rising demand from emerging markets of Asia have fuelled the market growth. However, pain and complications during surgery and asymptomatic nature of gallstones may slow the growth of the market. American Gastroenterological Association, NCBI, Gastroenterological Society of Australia, British Society of Gastroenterology Directorate of Industries, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation

Gallbladder Treatment Market Segment Insights

Global gall bladder treatment market has been segmented on the basis of disease indications, diagnosis, treatment and end users. 

Gallbladder Treatment Disease Indications Insights

On the basis of disease indications the market is segmented as gallstones, cholecystitis & biliary colic, cholelithiasis & choledocholithiasis, gallbladder polyps, gall bladder cancer. 

Gallbladder Treatment diagnosis Insights

On the basis of diagnosis the market is categorized as ultrasound, blood tests, computerized tomography (CT), cholangiography and hepatobiliary scintigraphy and others. 

Gallbladder Treatment Insights

On the basis of treatment the market is segmented into surgery, and drugs and on the basis of end users the market is divided into hospitals & gynecology clinics, academic & research centers and others.

Key Findings

• Ultrasound segment accounts for the largest market share in the global gall bladder treatment market while Computerized tomography (CT) segment is projected to grow at a CAGR of 8.3% during the forecast period from 2022 – 2030.


• Surgery segment accounts for the largest market share in the global gall bladder treatment market by Treatment, this segment is expected to reach USD 28,563.7 Million in 2030

Gallbladder Treatment Regional Insights     

Considering the global scenario of the market, North America dominates the global gall bladder treatment market owing to the presence of huge population suffering from gall bladder diseases. US holds the largest market share in North America gall bladder treatment market. In developed countries, 10–15% of adults have gallstones. Europe has the second largest market for the gall bladder treatment which is followed by Asia Pacific. Presence of well-developed healthcare sector and high healthcare expenditure, the gall bladder treatment market in Europe is growing at a CAGR of 6.8%. Asia Pacific is also witnessing a rapid growth in this market which is mainly due to rapidly increasing awareness of treatments, presence of huge population, rising healthcare expenditure and government support for research & development. Asia Pacific gall bladder treatment market is expected to grow at a CAGR of 7.0% during the forecasted period. The Middle East & Africa is expected to have limited growth.

Key players for global gall bladder treatment market   

Some of the major players in this market are: Boston Scientific Corporation

• Intuitive Surgical


• C. R. Bard, Inc.


• Dornier MedTech


• Koninklijke Philips N.V.


• B. Braun Melsungen AG


• Sanofi

The report for Global Gall Bladder Treatment Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions

Intended Audience

• Gall Bladder Products Manufacturers


• Gall Bladder Products Providers


• Medical Research Laboratories


• Research and Development (R&D) Companies


• Market Research and Consulting Service Providers


• Potential Investors